Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA review next year
The FDA has set a PDUFA target action date of 30 January 2025 for Vertex’s acute pain treatment therapy that is a non-opioid alternative.
The FDA has set a PDUFA target action date of 30 January 2025 for Vertex’s acute pain treatment therapy that is a non-opioid alternative.
What's Your Reaction?
